A nationwide Danish study presented at ECO2026 in Istanbul found that women initiating semaglutide (Wegovy) for weight management experienced a 7% reduction in triptan-class migraine medications after one year.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Wegovy initiation may cut migraine drug use 8% in women after one year
Nationwide Study Study type
Semaglutide (Wegovy) Drug studied
7% Reduction In Triptan Use Outcome
Women Subject group
One Year Post-Initiation Timeframe
1 Year follow-up period
7% triptan reduction